Skip to main content

Zai Collaborates with Geneseeq to Implement Personalized Cancer Care

Zai Lab of Shanghai will collaborate with Geneseeq Technology, a Toronto-China company, to integrate cutting-edge NGS services into clinical trials and advance precision care. The two companies will form business relationships based on Geneseeq's clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing services for Zai's cancer candidates. Zai has three cancer products approved in China and another 10-15 candidates in development, many of them based on companion biomarkers. More details.... Stock Symbol: (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.